Rapport Therapeutics (RAPP) Expected to Announce Quarterly Earnings on Thursday

Rapport Therapeutics (NASDAQ:RAPP) is expected to release its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect the company to post earnings of ($1.20) per share for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Rapport Therapeutics (NASDAQ:RAPP) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.07). On average, analysts expect Rapport Therapeutics to post ($4.08) EPS for the current fiscal year and ($5.05) EPS for the next fiscal year.

Rapport Therapeutics Stock Up 1.2%

Shares of RAPP stock opened at $25.44 on Wednesday. The stock has a 50-day simple moving average of $35.76 and a 200 day simple moving average of $35.55. Rapport Therapeutics has a fifty-two week low of $22.06 and a fifty-two week high of $52.93.

Insider Transactions at Rapport Therapeutics

In other news, Director John Maraganore acquired 9,411 shares of the stock in a transaction on Thursday, October 22nd. The shares were purchased at an average cost of $26.45 per share, for a total transaction of $248,920.95. Following the transaction, the director owned 9,411 shares in the company, valued at approximately $248,920.95. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Abraham Ceesay sold 28,958 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $48.01, for a total value of $1,390,273.58. Following the completion of the sale, the chief executive officer owned 486,108 shares of the company’s stock, valued at $23,338,045.08. The trade was a 5.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have acquired 1,031,174 shares of company stock worth $22,023,898 and have sold 97,976 shares worth $4,391,729. Company insiders own 12.48% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on RAPP shares. Raymond James Financial reissued a “strong-buy” rating and issued a $86.00 price target on shares of Rapport Therapeutics in a report on Tuesday, October 20th. Citigroup reaffirmed an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday, October 20th. Wells Fargo & Company dropped their target price on shares of Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating on the stock in a report on Wednesday, October 21st. HC Wainwright reissued a “buy” rating and set a $66.00 target price on shares of Rapport Therapeutics in a research note on Tuesday, October 20th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Rapport Therapeutics presently has an average rating of “Buy” and a consensus price target of $68.36.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.